Nicox has enrolled the first 12 patients in a phase 3 clinical trial evaluating NCX 470, a novel second-generation nitric oxide-donating bimatoprost analog.
A company press release describes the Mont Blanc trial as “a multiregional, double-masked, 3-month, parallel group, adaptive design trial evaluating the efficacy and safety of NCX 470 ophthalmic solution 0.065% and 0.1% compared to latanoprost ophthalmic solution 0.005% in patients with open-angle glaucoma or ocular hypertension.”
In the trial’s adaptive portion, one dose will be selected for a head-to-head 3-month safety
Uncategorized